Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM CLINICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

24 Y Female | CML-AP - 11 Yr | 3 TKI+ (T315I Mut.) | Treatment after Ponatinib

  • Beppe Saglio
  • Beppe Saglio's Avatar Topic Author
1 month 2 weeks ago - 1 month 2 weeks ago #1873 by Beppe Saglio
This is a very difficult situation. I substantially agree with Tim who suggested to try also the combination of ponatinib and asciminib. I wonder also if a short course of chemo AML like (FLAG or FLA-IDA) could help to restore at least in part the sensitivity to ponatinib or asciminib after recovery from aplasia. This type of chemo could also decrease the titer of DSA antibodies, facilitating a subsequent transplant, that in any case remains the final solution. Substantially I would treat this case as a Ph-positive AML (or CML BC) using TKIs before and after the transplant.
Last edit: 1 month 2 weeks ago by arlene.
Moderators: Melissa Davis-Bishop